BELLUS Health Inc. (TSE:BLU – Get Free Report)’s share price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$19.48 and traded as high as C$19.61. BELLUS Health shares last traded at C$19.48, with a volume of 28,666 shares traded.
BELLUS Health Stock Performance
The firm has a 50-day moving average of C$19.48. The company has a market cap of C$2.47 billion, a price-to-earnings ratio of -20.29 and a beta of -0.28. The company has a debt-to-equity ratio of 0.32, a quick ratio of 16.40 and a current ratio of 33.42.
About BELLUS Health
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
Further Reading
- Five stocks we like better than BELLUS Health
- 3 REITs to Buy and Hold for the Long Term
- Charles Schwab Fortifies its Uptrend on EPS Beat
- 3 Fintech Stocks With Good 2021 Prospects
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Canada Bond Market Holiday: How to Invest and Trade
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.
